Livzon Pharmaceutical Group Inc. (FRA:LP6)

Market Cap	3.44B -13.0%
Revenue (ttm)	1.42B -0.1%
Net Income	256.49M +5.8%
EPS	0.29 +8.9%
Shares Out	n/a
PE Ratio	13.41
Forward PE	12.74
Dividend	0.13 (4.28%)
Ex-Dividend Date	Jun 13, 2025

Volume	n/a
Average Volume	34
Open	3.040
Previous Close	3.080
Day's Range	3.040 - 3.040
52-Week Range	2.760 - 4.300
Beta	n/a
RSI	44.76
Earnings Date	Mar 25, 2026

About FRA:LP6

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate and perospirone hydrochloride...

• Industry: Pharmaceutical Preparations
• Founded: 1985
• Employees: 9,067
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LP6

Financial Performance

In 2024, FRA:LP6's revenue was 11.81 billion, a decrease of -4.97% compared to the previous year's 12.43 billion. Earnings were 2.06 billion, an increase of 5.50%.

Financial numbers in CNY